BRETYLIUM TOSYLATE INJECTION USP
SANDOZ CANADA INCORPORATED
View this drug's full profile page →
This is a national manufacturer shortage report. It does not confirm whether the product is unavailable at your local pharmacy — call ahead or ask your pharmacist.
Quick answers
Is BRETYLIUM TOSYLATE INJECTION USP discontinued in Canada?
Yes. The manufacturer has reported to Health Canada that BRETYLIUM TOSYLATE INJECTION USP 50MG has been permanently discontinued (last updated December 6, 2017). It is not expected to come back, so talk to your pharmacist or doctor about an alternative.
Why is BRETYLIUM TOSYLATE INJECTION USP not available?
The reason the manufacturer reported: Manufacturing issues.
What this means
Does this mean I need to switch medications right away?
Not necessarily right away, but this product will not be returning to the market.
What should I do?
Talk to your pharmacist or prescriber about your options well before your current supply runs out.
DIN
02185377
Strength
50MG
Dosage Form
SOLUTION
Route
INTRAMUSCULAR INTRAVENOUS
Active Ingredient
BRETYLIUM TOSYLATE
Tier
Unrated
Last Updated
2017-12-06
Reason for Shortage
Manufacturing issues
Past Reports for This Drug
BRETYLIUM TOSYLATE INJECTION USP has 2 shortage/discontinuation reports on file — this is one of them.
Other Products from SANDOZ CANADA INCORPORATED
Other Health Canada-approved products made by the same manufacturer — not necessarily related to this shortage, and not necessarily in shortage themselves.
200MG · DIN 02243098
5MG · DIN 02269198
500MCG · DIN 02248181
250MG · DIN 02242971
50MG · DIN 02242325
DIN 02495929
DIN 02495937
DIN 02495910
250MG · DIN 02246533
1MG · DIN 02548968
10MG · DIN 02513420
10MG · DIN 02236759